CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 24 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0,5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01326325
NCT01326325Phase 3Completed
CompareCT.gov

Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease

Assistance Publique - Hôpitaux de Paris·interventional·Posted Mar 30, 2011·Updated Aug 7, 2013

In Brief

A Phase 3 clinical trial evaluating Ketamine and NaCl for Pain. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Long-term opioid therapy is commonly administered for the management of severe cancer pain. Increasing doses of opioids are titrated against effects until analgesia is achieved or intolerable adverse effects occur. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been reported to improve analgesia in patients with uncontrolled pain receiving high doses of opioids. This study aims at determining the effectiveness of ketamine as an adjuvant to opioids in relieving cancer pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2011
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.3 years ago

Interventions

Ketaminedrug

Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days

NaCldrug

Drip continues of NaCl 0,9% in intravenous injection during 4 days